Patents by Inventor Janos ROSZIK

Janos ROSZIK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF SDHA AS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN UVEAL MELANOMA
    Publication number: 20240068047
    Abstract: Provided herein are methods for identifying expression of SDHA, MIF, and or monosomy 3 or disomy 3 status in sample to identify the sample as high-risk melanoma and/or the sensitivity to oxidative phosphorylation inhibitors. Also provided herein are methods for treating monosomy 3 uveal melanoma by administering a SDHA inhibitor in combination with an oxidative phosphorylation inhibitor.
    Type: Application
    Filed: September 7, 2023
    Publication date: February 29, 2024
    Applicant: Board of Regents, The University of Texas System
    Inventors: Chandrani CHATTOPADHYAY, Janos ROSZIK
  • Use of SDHA as a prognostic marker and therapeutic target in uveal melanoma
    Patent number: 11767564
    Abstract: Provided herein are methods for identifying expression of SDHA, MIF, and or monosomy 3 or disomy 3 status in sample to identify the sample as high-risk melanoma and/or the sensitivity to oxidative phosphorylation inhibitors. Also provided herein are methods for treating monosomy 3 uveal melanoma by administering a SDHA inhibitor in combination with an oxidative phosphorylation inhibitor.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: September 26, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Chandrani Chattopadhyay, Janos Roszik
  • HLA-restricted VGLL1 peptides and use thereof in promoting an immune response in a subject
    Patent number: 11684657
    Abstract: Provided herein are tumor-antigen VGLL1 specific peptides. Also provided herein are methods of generating VGLL1-specific T cells and their use for the treatment of cancer. In addition, the VGLL1-specific peptides may be used as a vaccine.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: June 27, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Gregory Lizée, Cassian Yee, Janos Roszik
  • SLC45A2 PEPTIDES FOR IMMUNOTHERAPY
    Publication number: 20210170002
    Abstract: Provided are SLC45A2 peptides that bind to MHC I (HLA-A2) on melanoma cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The SLC45A2 peptides may be therapeutically used to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.
    Type: Application
    Filed: November 6, 2020
    Publication date: June 10, 2021
    Inventors: Gregory Lizée, Cassian Yee, Patrick Hwu, Janos Roszik
  • USE OF SDHA AS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN UVEAL MELANOMA
    Publication number: 20200399704
    Abstract: Provided herein are methods for identifying expression of SDHA, MIF, and or monosomy 3 or disomy 3 status in sample to identify the sample as high-risk melanoma and/or the sensitivity to oxidative phosphorylation inhibitors. Also provided herein are methods for treating monosomy 3 uveal melanoma by administering a SDHA inhibitor in combination with an oxidative phosphorylation inhibitor.
    Type: Application
    Filed: October 25, 2018
    Publication date: December 24, 2020
    Applicant: Board of Regents, The University of Texas System
    Inventors: Chandrani CHATTOPADHYAY, Janos ROSZIK
  • HLA-RESTRICTED VGLL1 PEPTIDES AND USE THEREOF
    Publication number: 20200040079
    Abstract: Provided herein are tumor-antigen VGLL1 specific peptides. Also provided herein are methods of generating VGLL1-specific T cells and their use for the treatment of cancer. In addition, the VGLL1-specific peptides may be used as a vaccine.
    Type: Application
    Filed: October 5, 2017
    Publication date: February 6, 2020
    Applicant: Board of Regents, The University of Texas System
    Inventors: Gregory LIZÉE, Cassian YEE, Janos ROSZIK
  • SLC45A2 PEPTIDES FOR IMMUNOTHERAPY
    Publication number: 20190169262
    Abstract: Provided are SLC45A2 peptides that bind to MHC I (HLA-A2) on melanoma cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The SLC45 A2 peptides may be therapeutically used to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.
    Type: Application
    Filed: December 2, 2016
    Publication date: June 6, 2019
    Inventors: Gregory LIZÉE, Cassian YEE, Patrick HWU, Janos ROSZIK